Skip to content

Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis

Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01570972
Enrollment
103
Registered
2012-04-04
Start date
2010-02-28
Completion date
2017-04-30
Last updated
2020-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS), Schizoaffective Disorder, Schizophrenia

Keywords

schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, major depression with psychotic features, recent-onset psychosis, first-episode psychosis, cognitive behavioral therapy, multifamily group psychoeducation

Brief summary

Multifamily group psychoeducation \[MFG\] and group cognitive behavioral therapy \[GCBT\] are evidence-based treatments for first episode psychosis. However, like all treatments for psychotic disorders, neither MFG nor GCBT are perfect-some individuals who receive these interventions still experience a worsening of psychotic symptoms. Clarifying the mechanisms through which these interventions produce their clinical benefits and identifying the factors that may maximize an individual's response to MFG and GCBT could improve the clinical benefits facilitated by these two interventions.

Detailed description

Background There is growing evidence that the majority of the psychosocial deterioration that accompanies psychotic disorders occurs during the first few years of illness and that the prevention or delay of early deterioration may be associated with a better course of illness. Two interventions which have been shown to improve the course of recent-onset psychosis are multifamily group psychoeducation \[MFG\] and group cognitive behavioral therapy \[GCBT\]. Both family psychoeducation and cognitive behavioral therapy have been recommended as components of usual care for psychotic disorders by the Schizophrenia Patient Oriented Research Team convened by the U.S. Department of Health and Human Services (10) as well as other international health organizations. However, like all treatments for psychotic disorders, neither MFG nor GCBT are perfect-some individuals who receive these interventions still experience a worsening of psychotic symptoms. Clarifying the mechanisms through which these interventions produce their clinical benefits and identifying the factors that may maximize an individual's response to MFG and GCBT could improve the clinical benefits facilitated by these two interventions. Purpose and Objectives The goal of this study is to clarify the mechanisms through which MFG and GCBT produce their clinical benefits (i.e., mediators) and identify the factors that may maximize an individual's response to these two empirically-validated interventions (i.e., moderators). Methods All participants will be provided with 2 years of of GCBT and MFG and will complete regular assessments with regard to clinical and functional outcomes as well as potential mediators and moderators of these outcomes. Significance of the Study Clarifying the mechanisms through which these interventions produce their clinical benefits and identifying the factors that may maximize an individual's response to MFG and GCBT could lead to improvements in the treatment of first-episode psychosis.

Interventions

Sponsors

University of Arizona
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

(Individual with Recent-Onset Psychosis): * Diagnosis of a non-substance induced psychotic disorder (schizophrenia spectrum or affective spectrum) per the Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revised (DSM-IV-TR) criteria determined using the Structured Clinical Interview for the DSM-IV. * Age between 18-35 * Willing to participate in interventions at University of Arizona Medical Center South Campus * Willing to complete research assessments * Duration of psychotic symptoms of less than 5 years determined using the Symptom Onset in Schizophrenia inventory * Able to provide informed consent * Fluent in English * Willing to allow videotaping of group cognitive behavioral therapy sessions, multifamily group sessions, and family interaction task. Exclusion Criterion (Individual with Recent Onset Psychosis) * No evidence of mental retardation as defined as never having qualified to receive services from the Arizona Department of Economic Security, Division of Developmental Disabilities. Inclusion Criteria (Family Caregiver): * Must be someone that the individual with recent-onset psychosis identifies as providing support and care to the individual with recent-onset psychosis. Does not need to be a biological relative. * Must spend considerable time with the individual with recent-onset psychosis as defined at 10 hours or more of direct contact per week. * Willing to participate in participate in family intervention at University of Arizona Medical Center, South Campus for 2 years * Willing to complete research assessments * Able to provide informed consent * Fluent in English * Willing to allow videotaping of multifamily group sessions, Camberwell Family Interview, and family interaction task. Exclusion Criterion (Family Caregiver) * Diagnosis of a psychotic disorder.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in General level of functioning at 6 months, 12 months, 18 months, and 24 monthsBaseline, 6 months, 12 months, 18 months, 24 monthsGeneral level of functioning to be assessed using the General Assessment of Functioning (GAF) scale
Change from baseline in self-reported Physical Health at 6 months, 12 months, 18 months, and 24 monthsBaseline, 6 months, 12 months, 18 months, 24 monthsSelf-reported physical health assessed using the RAND-36 Health Survey
Change from baseline in Social and vocational Functioning at 6 months, 12 months, 18 months, and 24 monthsBaseline, 6 months, 12 months, 18 months, 24 monthsSocial and Vocational functioning to be assessed using the Social Functioning Scale
Change from baseline in Stage of Recovery at 6 months, 12 months, 18 months, and 24 monthsBaseline, 6 months, 12 months, 18 months, 24 monthsStage of recovery assessed using the Stage of Recovery Instrument
Change from baseline Service Utilization at 6 months, 12 months, 18 months, and 24 monthsBaseline, 6 months, 12 months, 18 months, 24 monthsService utilization as assessed using the Service Utilization Record Form
Change from Baseline Quality of Life at 6 months, 12 months, 18 months, and 24 monthsBaseline, 6 months, 12 months, 18 months, 24 monthsQuality of Life as assessed using the WHO Quality of Life Scale Brief

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026